Table 6.

Stratification of clinical T stage of the detectable prostate cancers according to subgrouping of PSA level

PSA (ng/ml)	No. of PC	T1	T2	T3	T4
0–4	21	4 (19.0%)	11 (52.4%)	6 (28.6%)	0 (0.0%)
4–10	61	2 (3.3%)	18 (29.5%)	23 (37.7%)	18 (29.5%)
10–20	123	12 (9.8%)	25 (20.3%)	38 (30.9%)	48 (39.0%)
20–100	146	8 (5.5%)	36 (24.6%)	43 (29.5%)	59 (40.4%)
≥ 100	87	0 (0.0%)	7 (8.0%)	29 (33.3%)	51 (58.7%)
Total	438	26 (6.0%)	97 (22.1%)	139 (31.7%)	176 (40.2%)

PSA prostate-specific antigen, PC prostate cancer